uniQure (NASDAQ:QURE) Shares Gap Down – Should You Sell?

uniQure (NASDAQ:QURE) shares gapped down before the market opened on Friday . The stock had previously closed at $18.05, but opened at $17.55. uniQure shares last traded at $17.73, with a volume of 41,727 shares changing hands.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research report on Tuesday, December 10th. Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. Leerink Partners lifted their target price on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. Finally, Royal Bank of Canada lifted their price objective on uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and a consensus target price of $33.88.

uniQure Price Performance

The stock’s fifty day simple moving average is $10.15 and its 200 day simple moving average is $7.52. The firm has a market capitalization of $890.05 million, a P/E ratio of -3.68 and a beta of 0.89. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. On average, equities research analysts predict that uniQure will post -3.82 EPS for the current year.

Insider Buying and Selling at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 4.74% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. abrdn plc grew its stake in uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after acquiring an additional 1,528,581 shares during the period. Franklin Resources Inc. acquired a new stake in shares of uniQure in the third quarter valued at about $7,360,000. Point72 Asset Management L.P. increased its stake in shares of uniQure by 336.1% during the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after purchasing an additional 752,889 shares in the last quarter. FMR LLC raised its position in shares of uniQure by 8,056.6% during the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after purchasing an additional 346,274 shares during the last quarter. Finally, Privium Fund Management B.V. lifted its stake in uniQure by 16.3% in the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after buying an additional 104,500 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.